Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.57 |
| ▸ | CA1 | P00915 | 3/20 | 0.57 |
| ▸ | CA2 | P00918 | 3/20 | 0.57 |
| ▸ | CA7 | P43166 | 3/20 | 0.57 |
| ▸ | CA9 | Q16790 | 3/20 | 0.57 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | CCR1 | P32246 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | PKLR | P30613 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | FASN | P49327 | 3/20 | 0.40 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4172413 | 0.90 | KDM4E (0.58) | CA12CA1CA2CA7CA9 | |
| SCHEMBL4181151 | 0.89 | CA12 (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL4183383 | 0.87 | CYP2C9 (0.44) | CA12CA1CA2CA7CA9 | |
| SCHEMBL4177346 | 0.85 | CA12 (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL4193612 | 0.81 | FASN (0.49) | CA12CA1CA2CA7CA9 | |
| SCHEMBL4186712 | 0.81 | PKLR (0.55) | KDM4ESMN1; SMN2HPGDPKLRTSHR | |
| SCHEMBL4187265 | 0.80 | PKLR (0.52) | PKLR | |
| SCHEMBL4199044 | 0.80 | CA12 (0.61) | CA12CA1CA2CA7CA9 | |
| SCHEMBL4179408 | 0.80 | FASN (0.59) | HPGDFASN | |
| SCHEMBL4191661 | 0.78 | FASN (0.49) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105305-A1 | Therapeutic Agents - 550 | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | US | disclosed |
| WO-2008075070-A1 | SULFONAMIDE DERIVATIVES FOR THERAPEUTIC USE AS FATTY ACID SYNTHASE INHIBITORS | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105305-A1 | Therapeutic Agents - 550 | FABP4, GPR119, FASN | CA12 2949/4885CA1 3297/4885CA2 2038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.